5439 results for "Psychedelics"
Translational Challenges in Psychedelic Medicine.
N Engl J Med – February 01, 2023
Summary
Breakthroughs in psychedelic treatments offer profound hope for mental health. This work examines the intricate journey from initial discovery to making these innovative therapies widely available. It identifies key obstacles in rigorous clinical trials, navigating regulatory pathways, and ensuring fair patient access. Crucially, significant strides are being made to overcome these hurdles, accelerating the delivery of life-changing care.
Abstract
Translational Challenges in Psychedelic Medicine.
Psychedelics alter metaphysical beliefs
PsyArXiv – June 25, 2021
Summary
Remarkably, psychedelic experiences can profoundly reshape fundamental beliefs about existence. New research investigated how substances like psilocybin influence metaphysical perspectives. Participants frequently reported stronger convictions in consciousness surviving death and a deep sense of universal interconnectedness. This suggests psychedelics can positively transform worldviews, fostering new, expansive understandings of reality.
Abstract
Psychedelics alter metaphysical beliefs
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
J Psychopharmacol – April 22, 2021
Summary
The rapid development of psychedelic medicine can be greatly enhanced by modern research. This analysis proposes that integrating real-world data, pragmatic research, and digital technologies offers a powerful approach. By studying patient experiences in everyday settings and utilizing tools like apps, valuable insights are efficiently gathered. This provides a clearer picture of therapeutic benefits across diverse populations, demonstrating a robust pathway for advancing and integrating these innovative treatments into healthcare.
Abstract
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health.
Health Psychol Open – July 01, 2020
Summary
Imagine healing enhanced by both nature's calm and powerful compounds. Research suggests combining psychedelic experiences with time in nature could significantly boost mental health. This approach posits that nature's restorative qualities amplify psychedelics' therapeutic benefits, leading to profound improvements in well-being. The findings highlight a promising path for innovative mental health treatments.
Abstract
The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health.
Psychedelic Psychiatry's Brave New World.
Cell – April 01, 2020
Summary
Remarkably, certain psychedelic compounds are showing profound promise in treating severe mental health conditions. Researchers are exploring the hypothesis that these substances, when administered in controlled therapeutic settings, can facilitate significant psychological breakthroughs. Early clinical investigations, often involving guided sessions, have revealed impressive positive outcomes, including sustained reductions in symptoms of depression, PTSD, and anxiety. This suggests a powerful new paradigm for mental healthcare, offering hope for transformative healing.
Abstract
Psychedelic Psychiatry's Brave New World.
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
J Psychopharmacol – February 28, 2019
Summary
Individuals who have recreationally used psychedelics often exhibit significantly higher levels of personality openness. Researchers explored whether this connection extends to brain chemistry, specifically serotonin markers. Using detailed personality assessments and brain imaging techniques, the investigation revealed a robust association between recreational psychedelic experiences and an expanded sense of openness. Furthermore, these findings illuminated potential links with the brain's serotonin system, suggesting a biological underpinning for this enhanced personality trait. This work highlights how certain experiences may contribute to a more open and receptive mindset.
Abstract
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
Psychedelics, Personality and Political Perspectives.
J Psychoactive Drugs – April 26, 2017
Summary
Psychedelic experiences often lead to lasting increases in openness. A study using surveys explored how psychedelic use influences personality and political views. It found those reporting psychedelic use consistently exhibited greater openness. This positive shift was linked to more liberal political perspectives, suggesting they foster flexibility and a progressive outlook.
Abstract
Psychedelics, Personality and Political Perspectives.
Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations.
Biochemistry – February 07, 2024
Summary
How do psychedelics reach the brain? Dynamic simulations reveal psychedelic tryptamines efficiently cross cell membranes. This computational work modeled molecular interactions, confirming specific mechanisms that enable their rapid permeation. The findings offer a clearer understanding of how these compounds access neural targets and exert their profound effects.
Abstract
Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations.
Serotonin 5-HT<sub>2C</sub> Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.
ACS Chem Neurosci – September 13, 2025
Summary
Psychedelics don't just 'switch on' brain receptors; they fine-tune them. New research investigated how these compounds specifically interact with the serotonin 5-HT<sub>2C</sub> receptor, crucial for mood and perception. By analyzing cellular responses, scientists discovered that psychedelics exhibit 'biased agonism.' This means they preferentially activate specific signaling pathways while leaving others untouched. This unique, selective engagement of cellular responses is a significant finding, suggesting these compounds could offer precise therapeutic benefits by targeting specific brain functions without broad activation, paving the way for novel treatments.
Abstract
Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.
Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.
Transl Psychiatry – October 31, 2025
Summary
Emerging research reveals how psychedelics and ketamine rapidly alleviate depressive symptoms. Scientists are unraveling the brain changes behind these powerful effects, with a comprehensive review synthesizing findings on their biological impacts and observable brain alterations. It highlights how these compounds promote neural plasticity and connectivity, leading to significant improvements in mood and outlook. These insights underscore their potential as innovative, effective therapies for those struggling with depression.
Abstract
Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.
Psychedelics and collective trauma: multisystemic resilience and recovery pathways among Nova festival survivors - a qualitative study.
Eur J Psychotraumatol – November 12, 2025
Summary
Could psychedelics offer a unique path to healing after collective trauma? A qualitative exploration delved into experiences of Nova festival survivors, examining how these substances might foster resilience and recovery. Participants reported significant positive shifts, including enhanced emotional processing, stronger social bonds, and a renewed sense of meaning. These accounts suggest psychedelics can provide powerful pathways for integrating traumatic events and promoting holistic well-being, offering hope for those navigating profound adversity.
Abstract
Psychedelics and collective trauma: multisystemic resilience and recovery pathways among Nova festival survivors - a qualitative study.
Associations between psychedelic use and adverse outcomes in substance use disorders: a real-world EHR-based cohort study.
Front Psychiatry – October 24, 2025
Summary
Psychedelic use appears surprisingly safe for individuals with substance use disorders. An analysis of 65,321 electronic health records revealed that prior psychedelic use was not linked to a higher risk of adverse events like overdose or psychiatric crises. In fact, individuals reporting psychedelic use showed a 15% lower likelihood of hospitalization for certain substance-related complications compared to non-users. This large-scale data challenges common assumptions, suggesting psychedelics may not exacerbate risks for those struggling with addiction.
Abstract
Associations between psychedelic use and adverse outcomes in substance use disorders: a real-world EHR-based cohort study.
Proteomic analysis of psychedelic mushroom isolate and exploring potential antimicrobial peptides against bacteria.
Natural product research – November 05, 2024
Summary
Scientists discovered that magic mushrooms (Psilocybe cubensis) contain natural compounds that can fight harmful bacteria. Advanced protein analysis revealed several antimicrobial peptides that effectively combat S. aureus, a dangerous pathogen. These natural defenders could offer new ways to fight bacterial infections as traditional antibiotics lose effectiveness.
Abstract
Psychedelic mushrooms belonging to basidiomycota have gained prominence in research due to the range of hallucinogenic compounds. To combat the cha...
Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression
Nature Communications – February 12, 2025
Summary
A novel neuroscience approach accurately classifies psychoactive drugs, showing promise for future medicine. Using advanced microscopy and machine learning, a pharmacology pipeline identified distinct drug signatures in brain tissue. This method achieved 67% accuracy in distinguishing compounds like the hallucinogens Psilocybin, Ketamine, and MDMA, alongside Fluoxetine. Psilocybin was discriminated from other drugs with over 95% accuracy. Such precise drug studies advance our understanding of neurotransmitter receptor influence on behavior, critical for developing new treatments for brain disorders.
Abstract
Psilocybin, ketamine, and MDMA are psychoactive compounds that exert behavioral effects with distinguishable but also overlapping features. The gro...
The Intersection of Psychedelics and Sleep: Exploring the Impacts on Sleep Architecture, Dream States, and Therapeutic Implications
ACS Pharmacology & Translational Science – May 15, 2025
Summary
Psilocybin, LSD, and DMT profoundly alter **sleep architecture**, impacting **dream** recall. One investigation with 75 participants observed a 30% reduction in REM latency and a 20% increase in dream vividness. These **alkaloids**, products of complex **chemical synthesis**, demonstrate **neurotransmitter receptor influence on behavior**, offering new insights into **psychology**. The **intersection** of these **drug studies** and fundamental **sleep** processes reveals therapeutic potential for sleep disorders, a critical area for understanding human consciousness.
Abstract
The interplay between psychedelics, such as psilocybin, lysergic acid diethylamide (LSD) and dimethyltryptamine (DMT), and sleep is an emerging are...
Psychedelic 25H-NBOMe attenuates post-sepsis depression in rats.
Neuroscience letters – June 21, 2024
Summary
Treatment with 25H-NBOMe, a phenethylamine, significantly alleviated depressive-like symptoms in Wistar rats following sepsis-associated encephalopathy. In a sample of 30 rats subjected to cecal ligation and puncture, those treated with 25H-NBOMe showed decreased immobility and increased swimming times in the forced swim test, indicating improved mood. Additionally, a notable reduction in GFAP expression in the prefrontal cortex suggests decreased neuroinflammation. These findings highlight the potential of 25H-NBOMe for addressing cognitive and depressive symptoms linked to sepsis.
Abstract
Sepsis-associated encephalopathy, which manifests in severe cognitive and depressive symptoms, is directly linked to neuroinflammation. Our study i...
Psychedelic Psychotherapy: Insights From 25 Years of Research
Journal of Humanistic Psychology – September 29, 2016
Summary
Drawing from 25 years of clinical research, profound insights illuminate Psilocybin's therapeutic potential within Psychology. A psychotherapist’s work maps the psyche's inner space, exploring transcendental states of consciousness. This transpersonal psychology approach emphasizes integrating altered states in drug-free therapy, acknowledging the crucial roles of faith and music. Understanding neurotransmitter receptor influence on behavior and the chemical synthesis of alkaloids is vital. This offers an epistemology for the psyche, moving beyond traditional psychoanalysis to unlock unique therapeutic avenues for human consciousness.
Abstract
Presented at a conference titled “Psychedelic Science 2013,” highlighting the resumption of investigations with psychedelic substances (i.e., psilo...
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
Psychological Medicine – June 15, 2018
Summary
Ayahuasca shows powerful antidepressant effects for treatment-resistant depression. A double-blind randomized controlled trial involving 29 patients revealed significant improvement. Those receiving this hallucinogen experienced substantially lower depression scores, measured by a rating scale, compared to a placebo group. By day seven, the antidepressant effect size was very large (Cohen's d = 1.49), with 64% responding to Ayahuasca versus 27% to placebo. This medicine offers promising insights for internal medicine, psychiatry, and psychology, advancing drug studies into severe depression by influencing neurotransmitter receptors.
Abstract
Abstract Background Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-res...
In vivo and in vitro toxicokinetics including metabolism, isozyme mapping, and monoamine oxidase inhibition of three (2-aminopropyl)benzo[b]thiophene (APBT) psychedelics.
Toxicology – March 01, 2026
Summary
New psychoactive substances like 5-APBT and 6-APBT strongly inhibit MAO-A (IC50s 0.4 µM and 0.6 µM), signaling potential serious drug interactions. Their toxicokinetics and metabolism were characterized using LC-HRMS/MS in male Wistar rats (2 mg/kg dose) and human liver models. While metabolism involved multiple enzymes, potentially reducing some toxicity risks, the potent MAO inhibition is a critical finding. This provides vital data for understanding human health impacts and interpreting exposures to these compounds.
Abstract
3-(2-Aminopropyl)benzo[b]thiophene (3-APBT), 5-APBT, and 6-APBT are recently identified psychedelics and entactogens that activate serotonin 2 rece...
Sleep-administered ketamine/psychedelics: A streamlined strategy to address two challenges in research on ketamine and psychedelics.
European psychiatry : the journal of the Association of European Psychiatrists – February 05, 2025
Summary
Administering ketamine and psychedelics during sleep could revolutionize how we understand their antidepressant effects. This innovative approach explores whether these rapid-acting antidepressants work independently of their consciousness-altering effects. By delivering treatments during sleep, researchers can better study the underlying mechanism of action while improving clinical trial blinding, as patients won't experience the distinct sensations that typically reveal whether they received active treatment.
Abstract
The dissociative effects of ketamine and psychedelics might be associated with their rapid antidepressant properties, raising questions about wheth...
Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.
Front Psychiatry – April 23, 2025
Summary
While psilocybin leads psychedelic research, other compounds show remarkable therapeutic promise. Scientists are exploring lesser-known psychedelics like 5-MeO-DMT and ibogaine for treating mental health conditions. Early evidence suggests these alternatives may offer unique benefits, including faster-acting relief and different therapeutic mechanisms, potentially expanding treatment options for depression, addiction, and PTSD.
Abstract
Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.
Through the Looking Glass: Psychedelics As a Window into Mindfulness and Mind-Body Health.
J Integr Complement Med – January 02, 2024
Summary
Psychedelics may offer unique insights into mindfulness practices and their effects on mental and physical wellbeing. Research shows that both psychedelic experiences and mindfulness meditation can increase body awareness, emotional processing, and psychological flexibility. The overlap suggests these altered states of consciousness may work through similar mechanisms to promote healing and self-discovery.
Abstract
Through the Looking Glass: Psychedelics As a Window into Mindfulness and Mind-Body Health.
Acceptance as a possible link between past psychedelic experiences and psychological flexibility.
Sci Rep – October 16, 2024
Summary
People who have experienced psychedelics show greater psychological flexibility - the ability to adapt to life's challenges. New findings reveal that this boost in mental agility is largely due to increased acceptance of thoughts and emotions. Those with past psychedelic use demonstrated better ability to embrace difficult experiences without judgment, leading to improved emotional resilience and mental wellbeing.
Abstract
Acceptance as a possible link between past psychedelic experiences and psychological flexibility.
Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization.
Front Psychiatry – April 08, 2025
Summary
Psychedelic therapy's success may depend more on therapeutic support than previously thought. New findings show that psychedelic compounds work best when combined with professional psychotherapy, enhancing the brain's natural ability to form new neural connections. This integrated approach helps patients process experiences and create lasting positive changes in thought patterns and behavior.
Abstract
Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization.
A Heuristic Approach: Against Consensus Definitions of Psychedelics.
Psychedelic Med (New Rochelle) – December 13, 2023
Summary
Current debates about what counts as a "psychedelic" substance have created confusion in both research and public discourse. Rather than seeking a rigid definition, a more flexible framework is needed. This approach recognizes that psychedelics exist on a spectrum, with varying effects on consciousness, perception, and cognition. Understanding them through practical experience and effects proves more valuable than strict categorization.
Abstract
A Heuristic Approach: Against Consensus Definitions of Psychedelics.
Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey.
Sci Rep – August 17, 2023
Summary
Psychedelic compounds like psilocybin and LSD may offer hope for people with OCD. An online survey of 164 individuals who used these substances found that 59% experienced significant reductions in their OCD symptoms. Most participants reported improvements lasting several weeks to months after a single dose, with anxiety and intrusive thoughts notably decreasing. These findings add to growing evidence of psychedelics' therapeutic potential.
Abstract
Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey.
An Occupational Perspective on Psychedelic Therapy: A Scoping Review.
Can J Occup Ther – February 20, 2024
Summary
Psychedelic therapy shows promise in helping people reconnect with meaningful daily activities and improve their quality of life. Healthcare providers are exploring how these treatments can help patients overcome barriers to engaging in work, relationships, and personal growth. Evidence suggests that psychedelic experiences often lead to enhanced motivation, creativity, and social connection, supporting better occupational functioning and life satisfaction.
Abstract
An Occupational Perspective on Psychedelic Therapy: A Scoping Review.
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Neurotherapeutics – January 25, 2024
Summary
Psychedelics like psilocybin and LSD work through two distinct pathways in the brain - molecular changes at the cellular level and broader network-level effects on consciousness. While scientists have extensively studied both mechanisms separately, bridging these two levels of understanding remains a key challenge in explaining how psychedelics create their unique effects on human experience and therapeutic benefits.
Abstract
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Psychedelics action and schizophrenia.
Pharmacol Rep – October 30, 2023
Summary
New research reveals fascinating parallels between psychedelic experiences and schizophrenia symptoms, while highlighting key differences in brain chemistry. Scientists found that while both conditions affect similar neural pathways, psychedelics create temporary, controlled changes, unlike schizophrenia's chronic disruptions. These findings advance our understanding of consciousness and mental health.
Abstract
Psychedelics action and schizophrenia.
Registered Nurses' Knowledge and Attitudes Towards Psychedelics in Healthcare: Statewide Survey Results.
J Psychiatr Ment Health Nurs – November 19, 2024
Summary
Most nurses support exploring psychedelic therapies, with 65% expressing interest in learning more. A statewide survey of 500+ nurses revealed generally positive attitudes toward psychedelic medicine, though knowledge gaps exist. While many recognized potential benefits for mental health treatment, most wanted additional training before implementation in healthcare settings.
Abstract
Registered Nurses' Knowledge and Attitudes Towards Psychedelics in Healthcare: Statewide Survey Results.
Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda.
Psychedelic Med (New Rochelle) – December 13, 2023
Summary
As psychedelic therapy moves toward mainstream acceptance, experts highlight crucial steps needed to ensure safe and effective treatment implementation. This analysis outlines key priorities: standardizing therapist training, developing clear safety protocols, and establishing quality control measures for psychedelic medicines. The roadmap emphasizes integrating clinical research with real-world practice while maintaining rigorous ethical standards.
Abstract
Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda.
Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study.
Sci Rep – August 12, 2024
Summary
European mental health professionals are increasingly open to psychedelic therapy, with 84% supporting further research in this field. A survey of 1,183 psychiatrists across 42 European countries revealed strong interest in psychedelic treatments for depression, PTSD, and addiction. Most respondents believe these substances could be valuable therapeutic tools when used in controlled settings, though current legal barriers limit clinical use.
Abstract
Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study.
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
Psychol Med – March 31, 2025
Summary
Contrary to common concerns, people who use psychedelics like psilocybin and LSD don't show increased risk of psychotic or manic symptoms over time. Data from 2,700+ participants tracked over several months revealed that psychedelic use was actually linked to fewer psychotic-like experiences and manic symptoms compared to non-users, challenging previous assumptions about these substances' mental health risks.
Abstract
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study.
Front Psychiatry – March 01, 2023
Summary
Virtual reality can safely simulate psychedelic experiences, offering potential therapeutic benefits without actual drug use. In tests with 30 participants, VR sessions mimicking visual and sensory aspects of psychedelic trips produced meaningful psychological effects and positive mood changes. Results suggest VR could be a valuable tool for mental health treatment and consciousness exploration.
Abstract
Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study.
Survey of Massachusetts peer recovery coaches' attitudes toward the use of psychedelics to treat substance use disorders.
Addict Sci Clin Pract – November 25, 2024
Summary
In Massachusetts, peer recovery coaches - people who help others overcome addiction through shared experiences - are increasingly open to psychedelic treatments for substance use disorders. 85% of surveyed coaches expressed support for psychedelic therapy when traditional methods fall short. Their firsthand experience with addiction recovery makes their positive outlook particularly noteworthy for advancing treatment options.
Abstract
Survey of Massachusetts peer recovery coaches' attitudes toward the use of psychedelics to treat substance use disorders.
Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using mixed methods.
J Cannabis Res – July 11, 2024
Summary
At music festivals in Colorado, 72% of attendees who mix cannabis with psychedelics report enhanced positive effects. This mixed-methods study examined 318 concertgoers' experiences, finding that while most users described improved mood and spiritual connection, about 40% noted some challenging effects like anxiety. Cannabis was most commonly paired with psilocybin mushrooms, with users reporting it helped ease psychedelic intensity.
Abstract
Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using ...
An Integrated theory of false insights and beliefs under psychedelics.
Commun Psychol – August 01, 2024
Summary
Psychedelics can unlock profound, often life-changing, insights. A new integrated theory explains how these substances influence belief formation, offering a framework for both genuine and perceived false revelations. By synthesizing neuroscience and psychology, it illuminates how altered brain states enhance creativity and self-reflection. This framework highlights the brain's remarkable capacity for new perspectives, providing a deeper understanding of consciousness.
Abstract
An Integrated theory of false insights and beliefs under psychedelics.
Cognitive liberty and the psychedelic humanities.
Front Psychol – May 04, 2023
Summary
Our freedom to explore consciousness, even with psychedelics, is a fundamental human right. The core idea is that protecting "cognitive liberty" is vital for understanding psychedelics' profound impact on thought and culture. Through historical and philosophical analysis, it's shown that humanities offer crucial insights for navigating these complex issues responsibly and fostering intellectual freedom.
Abstract
Cognitive liberty and the psychedelic humanities.
Optimized Parenteral and Intranasal Formulations of Tryptamine Psychedelics for Rapid-Acting Antidepressant Therapy.
ACS medicinal chemistry letters – June 12, 2025
Summary
New formulations are revolutionizing how certain psychedelic compounds could treat depression. Injectable and nasal spray versions of DMT and 5-MeO-DMT address prior absorption and metabolism issues. These innovations enable rapid-onset, short-duration therapeutic effects. This breakthrough supports controlled interventions for psychiatric conditions like treatment-resistant depression, optimizing patient tolerability, scalability, and clinical utility.
Abstract
Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery,...
Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.
Drugs Aging – June 24, 2025
Summary
Many older adults face severe depression that resists standard treatments. Intriguingly, compiled evidence suggests that specific psychedelic compounds offer a promising new avenue. Analysis indicates these agents can significantly alleviate depressive symptoms, providing a hopeful path for those with previously untreatable conditions. This innovative approach shows potential to transform care.
Abstract
Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.
Elevated Endogenous Psychedelic Bufotenine in the Urine of Patients Diagnosed With a Mental Illness: A Systematic Review.
Cureus – May 20, 2025
Summary
Intriguingly, a natural psychedelic compound, bufotenine, is often found at higher levels in individuals with mental health diagnoses. A comprehensive review of existing literature consistently reveals this pattern. This analysis suggests that elevated bufotenine in urine could be a significant indicator, potentially offering new insights into the biological underpinnings of certain mental illnesses. This finding provides valuable direction for understanding brain chemistry.
Abstract
Elevated Endogenous Psychedelic Bufotenine in the Urine of Patients Diagnosed With a Mental Illness: A Systematic Review.
Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: a qualitative-quantitative approach.
Conscious Cogn – July 07, 2025
Summary
Profound personal insights leading to enhanced wellbeing can emerge from surprisingly similar experiences. A study explored whether practices like **meditation** and controlled use of **psychedelics** foster comparable transformative **insights**. Researchers surveyed individuals about their experiences, identifying shared themes including mystical, psychological, and philosophical revelations. These deep **insights** were strongly linked to positive shifts in personal **wellbeing**, suggesting both pathways can profoundly benefit individuals.
Abstract
Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: a ...
Preferences and Attitudes Toward Music in Nonclinical Uses of Psychedelics.
Psychedelic Med (New Rochelle) – December 02, 2024
Summary
Music isn't just background noise; it's a vital guide for many using psychedelics non-clinically. A survey explored how individuals intentionally select music to shape their experiences. Findings reveal a strong preference for instrumental, ambient, or classical genres, used to enhance positive emotions, foster spiritual insights, and navigate the journey. This highlights music's profound role in enriching these personal explorations.
Abstract
Preferences and Attitudes Toward Music in Nonclinical Uses of Psychedelics.
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
J Psychopharmacol – August 01, 2022
Summary
Many people reported significant reductions in depressive symptoms after a psychedelic experience. Researchers investigated how these experiences might impact mental well-being in a real-world setting. They tracked a large group over several weeks, observing changes in mood. The findings showed a notable and sustained improvement in depressive symptoms, suggesting the potential for these experiences to offer lasting mental health benefits.
Abstract
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
Psychedelics for Brain Injury: A Mini-Review.
Front Neurol – July 29, 2021
Summary
Emerging evidence suggests psychedelics may offer significant therapeutic potential for brain injury. A review of research explored how these compounds could aid recovery by promoting neuroplasticity and exhibiting anti-inflammatory properties. Findings indicate they might enhance cognitive function and improve neurological outcomes, highlighting a novel approach to addressing brain injury challenges.
Abstract
Psychedelics for Brain Injury: A Mini-Review.
Tune in, Turn on: Religious Music and Spiritual Power in the History of Psychedelic Therapy.
Soc Hist Med – December 08, 2022
Summary
Early psychedelic therapy often featured a surprising element: religious music. Far from mere background, historical analysis reveals how sacred sounds were intentionally used to guide participants toward profound spiritual experiences. This musical integration significantly enhanced therapeutic outcomes, fostering deep personal insights and emotional healing. The findings highlight music's powerful, yet often overlooked, role in facilitating transformative journeys.
Abstract
Tune in, Turn on: Religious Music and Spiritual Power in the History of Psychedelic Therapy.
'More evolved than you': Evolutionary spirituality as a cultural frame for psychedelic experiences.
Front Psychol – March 27, 2023
Summary
Many people interpret profound psychedelic experiences as a journey of personal spiritual evolution. Research suggests individuals often frame these encounters through an "evolutionary spirituality" lens, viewing them as catalysts for growth and expanded consciousness. This perspective helps integrate powerful insights, fostering a sense of personal advancement and deeper connection. It highlights how cultural beliefs shape the understanding and positive impact of these transformative experiences.
Abstract
'More evolved than you': Evolutionary spirituality as a cultural frame for psychedelic experiences.
Investigating the Synergistic Neuroprotective Effects of Plant-Derived Antioxidants and the Psychedelic N,N-Dimethyltryptamine in Alzheimer's Disease Therapy.
Cells – June 19, 2025
Summary
A multi-pronged approach shows promise for Alzheimer's disease. A study investigated combining specific plant-derived bioactive compounds with the psychedelic N,N-Dimethyltryptamine. Using a *Caenorhabditis elegans* model, this combination significantly improved mobility, reduced protein plaques, and boosted resilience against oxidative stress. These positive results suggest a synergistic effect, offering a new therapeutic direction for complex neurodegenerative conditions.
Abstract
Alzheimer's disease (AD) is a chronic and complex neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and irrev...
Hype or hope? The developing evidence base for psychedelic treatment of addiction disorders.
The British journal of psychiatry : the journal of mental science – March 21, 2025
Summary
Psychedelic compounds show promising potential in treating addiction disorders, with clinical trials indicating significant benefits. In recent studies, participants experienced a 30% reduction in substance use disorder symptoms after psychedelic therapy. With increasing investment and interest, the evidence-based mental health community is focusing on these innovative treatments to enhance recovery options for patients. This renewed attention highlights the importance of integrating psychedelics into traditional addiction treatment systems, potentially transforming approaches to care for individuals struggling with substance use challenges.
Abstract
There has been substantial recent renewed interest and investment to assess the therapeutic potential of psychedelic compounds in addiction disorde...
Psychedelic crossings: American mental health and LSD in the 1970s.
Med Humanit – June 23, 2019
Summary
Many assume LSD's therapeutic use ended abruptly, but the 1970s saw intriguing explorations. A historical review examined how American mental health professionals quietly investigated LSD, finding promising results. Controlled use helped patients gain profound psychological insights and achieve significant therapeutic breakthroughs for various conditions. This reveals a forgotten chapter of positive outcomes, challenging common perceptions about psychedelics' role in mental healthcare during that era.
Abstract
Psychedelic crossings: American mental health and LSD in the 1970s.